Print Page  |  Close Window

Debt Information

Teva's senior notes and debentures and convertible debentures are issued by various special-purpose finance subsidiaries. All such debt is guaranteed by Teva Pharmaceutical Industries Ltd.


Quarterly Debt Factsheet

Senior Notes and Debentures

Issued
Currency
Annual
Interest
Principal Amount
Issued
Current
Outstanding
Due
Prospectuses
    (%) (U.S. $ in MM)
January 2006USD6.1501,000782January 2036
November 2011USD3.6501,7501,209November 2021
April 2012CHF1.500459458October 2018
December 2012USD2.250700700March 2020
December 2012USD2.9501,300862December 2022
March 2015Euro1.2501,4461,501March 2023
March 2015Euro1.875779810March 2027
July 2016USD1.7002,0001,700July 2019
July 2016USD2.2003,0002,997July 2021
July 2016USD2.8003,0002,993July 2023
July 2016USD3.1503,5003,493October 2026
July 2016USD4.1002,0001,984October 2046
July 2016CHF0.1253060July 2018
July 2016CHF0.500357357July 2022
July 2016CHF1.000357357July 2025
July 2016Euro0.3751,9471,924July 2020
July 2016Euro1.1251,6691,731October 2024
July 2016Euro1.625834863October 2028
March 2018USD6.0001,2501,250April 2024
March 2018USD6.7501,2501,250March 2028
March 2018Euro3.250867812April 2022
March 2018Euro4.5001,1151,045March 2025



Convertible Senior Debentures

Issued
Annual interest rate
Initial Principal amount
Principal amount at 3/31/2017
Year due
Conversion price August 2018
No of Teva shares issuable upon full conversion at 3/31/2017
Earliest date of redemption at issuer's option / repurchase at holder's option
  (%) (U.S. $ in MM)   (U.S. $)(in MM) 
January 2006(1)0.25$575$5142026$39.7841See footnote 1 Issuer - on demand
Holders - on 2/1/2021

To view the prospectus supplement relating to the January 2006 debentures - click here

For conversion and other notices - click here


(1) These convertible senior debentures due 2026 include a "net share settlement" feature according to which the principal of the debentures will be paid in cash and in the case of conversion, only the residual conversion value above the principal will be paid in Teva shares.



Term Loans and Other Facilities

Source
Year
of
Facility
Currency
Annual
Interest Rate (%)
Principal Amount
Issued
Due
Additional Information
      (%) (U.S. $ in MM)  

Revolving Credit Facility*

2015USDUSD Libor +1.875-N/A$3.0 b facility available for 5 years

*The following amendments document apply to the term loans and revolving credit facility noted above

 Covenant Amendments – February 2018
 Covenant Amendments – September 2017